Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy
Open Access
- 16 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (1), 105-118
- https://doi.org/10.1093/brain/awab304
Abstract
Metachromatic leukodystrophy is a lethal metabolic leukodystrophy, with emerging treatments for early disease stages. Biomarkers to measure disease activity are required for clinical assessment and treatment follow-up. This retrospective study compared neurofilament light chain and glial fibrillary acidic protein levels in CSF (n = 11) and blood (n = 92) samples of 40 patients with metachromatic leukodystrophy (aged 0–42 years) with 38 neurologically healthy children (aged 0–17 years) and 38 healthy adults (aged 18–45 years), and analyzed the associations between these levels with clinical phenotype and disease evolution in untreated and transplanted patients. Metachromatic leukodystrophy subtype was determined based on the (expected) age of symptom onset. Disease activity was assessed by measuring gross motor function deterioration and brain MRI. Longitudinal analyses with measurements up to 23 years after diagnosis were performed using linear mixed models. CSF and blood neurofilament light chain and glial fibrillary acidic protein levels in pediatric controls were negatively associated with age (all P < 0.001). Blood neurofilament light chain level at diagnosis (median, interquartile range; picogram per milliliter) was significantly increased in both pre-symptomatic (14.7, 10.6–56.7) and symptomatic patients (136, 40.8–445) compared to controls (5.6, 4.5–7.1), and highest amongst patients with late-infantile (456, 201–854) or early-juvenile MLD (291.0, 104–445) and those ineligible for treatment based on best practice (291, 57.4–472). Glial fibrillary acidic protein level (median, interquartile range; picogram per milliliter) was only increased in symptomatic patients (591, 224–1150) compared to controls (119, 78.2–338) and not significantly associated with treatment eligibility (P = 0.093). Higher blood neurofilament light chain and glial fibrillary acidic protein levels at diagnosis were associated with rapid disease progression in late-infantile (P = 0.006 and P = 0.051, respectively) and early-juvenile patients (P = 0.048 and P = 0.039, respectively). Finally, blood neurofilament light chain and glial fibrillary acidic protein levels decreased during follow-up in untreated and transplanted patients but remained elevated compared with controls. Only neurofilament light chain levels were associated with MRI deterioration (P < 0.001). This study indicates that both proteins may be considered as non-invasive biomarkers for clinical phenotype and disease stage at clinical assessment, and that neurofilament light chain might enable neurologists to make better informed treatment decisions. In addition, neurofilament light chain holds promise assessing treatment response. Importantly, both biomarkers require pediatric reference values, given that their levels first decrease before increasing with advancing age.Keywords
Funding Information
- Dutch charity organization Metakids
- European Commission
- Marie Curie International Training Network (860197 (MIRIADE) and JPND)
- Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands and the Alzheimer Association
This publication has 52 references indexed in Scilit:
- The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISAJournal of Immunological Methods, 2014
- Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter StudyPediatric Neurology, 2013
- Review on intermediate filaments of the nervous system and their pathological alterationsHistochemistry and Cell Biology, 2013
- Neurodevelopmental Outcomes of Umbilical Cord Blood Transplantation in Metachromatic LeukodystrophyTransplantation and Cellular Therapy, 2013
- The natural course of gross motor deterioration in metachromatic leukodystrophyDevelopmental Medicine and Child Neurology, 2011
- Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical courseJournal of Inherited Metabolic Disease, 2011
- Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophyDevelopmental Medicine and Child Neurology, 2010
- Metachromatic Leukodystrophy: A Scoring System for Brain MR Imaging ObservationsAmerican Journal of Neuroradiology, 2009
- CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndromeNeurology, 2006
- Axon Branch Removal at Developing Synapses by Axosome SheddingNeuron, 2004